Bridgeway Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History
Bought
Maintained
Sold
Other funds holding KPTI
ACA
Bridgeway Capital Management's KPTI Position: Q3 2026 in Review
Bridgeway Capital Management reduced its Karyopharm Therapeutics (KPTI) stake by 0.54% in Q3 2026, selling an estimated $1.6K and leaving 71,483 shares worth $87.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1145.
Bridgeway Capital Management first reported a position in KPTI in Q3 2023 and has held it in 12 quarters since. The position peaked at $702K in Q2 2026. 92 funds tracked by Wall St. Rank hold KPTI as of Q3 2026.
- Bridgeway Capital Management held 71,483 shares of Karyopharm Therapeutics worth $87.2K as of Q3 2026.
- Bridgeway Capital Management sold 390 Karyopharm Therapeutics shares in Q3 2026, an estimated $1.6K.
- Karyopharm Therapeutics made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q3 2026, its #1145 holding.
- Bridgeway Capital Management first reported a position in Karyopharm Therapeutics in Q3 2023 and has held it in 12 quarters since.
- Bridgeway Capital Management's Karyopharm Therapeutics position peaked at $702K in Q2 2026.
- 92 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2026.
Based on Bridgeway Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.